COVID-19 vaccine: Serum Institute's COVAX to get regulatory nod for emergency use in next few days

By Lokmat English Desk | Published: December 28, 2020 06:00 PM2020-12-28T18:00:52+5:302020-12-28T18:07:28+5:30

The world's largest vaccine maker, Serum Institute of India, which is also manufacturing the Oxford-AstraZeneca coronavirus vaccine in India, ...

COVID-19 vaccine: Serum Institute's COVAX to get regulatory nod for emergency use in next few days | COVID-19 vaccine: Serum Institute's COVAX to get regulatory nod for emergency use in next few days

COVID-19 vaccine: Serum Institute's COVAX to get regulatory nod for emergency use in next few days

The world's largest vaccine maker, Serum Institute of India, which is also manufacturing the Oxford-AstraZeneca coronavirus vaccine in India, said on Monday it expected the government to approve the shot for emergency use in a few days, reported Reuters.

Serum Chief Executive Adar Poonawalla also told reporters that the company had already made 40 million to 50 million doses of the vaccine.

We have 40-50 million doses of Covishield stockpiled. Once we get regulatory approvals in a few days, it'll be down to the Govt to decide how much they can take and how fast. We will be producing around 300 million doses by July 2021, said Adar Poonawalla, Serum Institute of India

India is a part of 'COVAX'. We will keep giving 50% of everything we make to India & to COVAX at the same time. India has such a large population that we will probably end up giving the majority of those 50 million doses to India first, he further added.

Serum Institute is the frontrunner in the vaccine race to find the silver bullet.

Open in app